Study: MRI bests PET in preoperative detection of prostate cancer

MRI had a higher sensitivity and accuracy than 11C-choline PET (C-PET) and 18F-fluorodeoxyglucose PET (FDG-PET), according to a study published online April 23 in the Journal of Magnetic Resonance Imaging.

Haruo Watanabe, MD from department of radiology at Gifu University Hospital, Japan, and colleagues obtained C-PET, FDG-PET and MR images from 43 consecutive patients with suspected prostate cancer. In 26 patients prostate cancers were histopathologically confirmed.

PET and MR images were reviewed at random by a nuclear and a genitourinary radiologist retrospectively and assigned a confidence level for the presence of prostate cancer using a four-point scale.

Watanabe and colleagues found that the sensitivity was greater with MR (88 percent) and C-PET (73 percent) images than with FDG-PET images (31 percent). The accuracy was greater with MR images (88 percent) than with C-PET (67 percent) and FDG-PET (53 percent) images.

C-PET and FDG-PET did not improve the detection and MRI should be primarily performed in the preoperative detection of prostate cancer, concluded Watanabe and colleagues.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.